NASDAQ:FEMY

Femasys - FEMY Stock Forecast, Price & News

$1.08

-0.05 (-4.42%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.04
▼
$1.14
50-Day Range: $1.05
▼
$1.41
52-Week Range: $0.99
▼
$5.64

Volume: 17,445 shs
Average Volume: 16,122 shs
Market Capitalization: $12.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.33

Femasys MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 579.0% Upside
$7.33 Price Target
Short Interest: Healthy
0.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.98) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

260th out of 1,047 stocks

Surgical & Medical Instruments Industry

30th out of 104 stocks

3.5

Analyst's Opinion

Consensus Rating
Femasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.33, Femasys has a forecasted upside of 579.0% from its current price of $1.08.
Amount of Analyst Coverage
Femasys has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.12% of the float of Femasys has been sold short.
Short Interest Ratio / Days to Cover
Femasys has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Femasys has recently decreased by 56.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Femasys does not currently pay a dividend.
Dividend Growth
Femasys does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FEMY.

1.9

News and Social Media Coverage

News Sentiment
Femasys has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Femasys this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 2 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Femasys insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.78% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.87% of the stock of Femasys is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Femasys are expected to grow in the coming year, from ($0.98) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Femasys is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Femasys is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Femasys has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Femasys

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

FEMY Stock News Headlines

November 29, 2022 | finance.yahoo.com

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

November 21, 2022 | finance.yahoo.com

Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference

November 12, 2022 | finance.yahoo.com

Femasys Third Quarter 2022 Earnings: Misses Expectations

November 10, 2022 | finance.yahoo.com

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

November 10, 2022 | finance.yahoo.com

Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates

October 20, 2022 | finance.yahoo.com

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

October 14, 2022 | benzinga.com

Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

October 14, 2022 | finance.yahoo.com

Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

October 12, 2022 | finance.yahoo.com

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

October 6, 2022 | finance.yahoo.com

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

September 29, 2022 | finance.yahoo.com

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

September 22, 2022 | uk.finance.yahoo.com

Femasys Inc. (FEMY)

September 1, 2022 | finance.yahoo.com

Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | seekingalpha.com

Femasys (FEMY) Investor Presnetation - Slideshow

August 10, 2022 | finance.yahoo.com

Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates

August 10, 2022 | finance.yahoo.com

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

August 3, 2022 | finance.yahoo.com

Femasys To Participate in Upcoming BTIG Biotechnology Conference

July 11, 2022 | finance.yahoo.com

Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET

July 6, 2022 | finance.yahoo.com

Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board

June 15, 2022 | finance.yahoo.com

Femasys Inc. to Present at the LSX World Congress USA 2022

June 5, 2022 | benzinga.com

Femasys (NASDAQ:FEMY), Earnings Estimates, EPS, and Revenue

May 21, 2022 | finance.yahoo.com

Is Femasys (NASDAQ:FEMY) In A Good Position To Invest In Growth?

May 11, 2022 | finance.yahoo.com

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022

March 25, 2022 | benzinga.com

Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference

March 24, 2022 | seekingalpha.com

CENN, TMC and QTT among pre market gainers

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

FEMY Company Calendar

Last Earnings: 11/10/2021
Today: 12/01/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FEMY
CUSIP: N/A
CIK: 1339005
Web: www.femasys.com
Phone: 770-500-3910
Fax: N/A
Employees: 27
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.33
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +579.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,540,000.00
Net Margins: -886.22%
Pretax Margin: -885.89%
Return on Equity: -48.96%
Return on Assets: -44.68%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 9.56
Quick Ratio: 9.37

Sales & Book Value

Annual Sales: $1.18 million
Price / Sales: 10.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.52 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 11,810,000
Free Float: 9,359,000
Market Cap: $12.75 million
Optionable: Not Optionable
Beta: -0.27

Key Executives

Ms. Kathy Lee-Sepsick (Age 55)
Founder & CEO and Pres
Comp: $566.72k

Mr. Daniel Scott Currie (Age 58)
SVP of Operations & Sec.
Comp: $411.46k

Mr. Dov Elefant (Age 55)
Chief Financial Officer

Ms. Mary An Merchant J.D.
Ph.D., VP of Counsel & Intellectual Property

Mr. Steven P. Damon (Age 66)
VP of Bus. Devel.

Mr. Todd A. Creech MBA (Age 54)
Chief Financial Advisor

Dr. Jeffrey Marcus M.D.
M.S., Chief Medical Advisor

Dr. Edward G. Evantash M.D. (Age 59)
Chief Medical Officer

Ms. Christine Thomas
Sr. VP of Regulatory & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FEMY Stock - Frequently Asked Questions

Should I buy or sell Femasys stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FEMY shares.
View FEMY analyst ratings or view top-rated stocks.
What is Femasys' stock price forecast for 2023?: 3 Wall Street analysts have issued twelve-month price objectives for Femasys' stock. Their FEMY share price forecasts range from $5.00 to $12.00. On average, they predict the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 579.0% from the stock's current price.
View analysts price targets for FEMY or view top-rated stocks among Wall Street analysts.
How have FEMY shares performed in 2022?: Femasys' stock was trading at $3.90 at the beginning of the year. Since then, FEMY shares have decreased by 72.3% and is now trading at $1.08.
View the best growth stocks for 2022 here.
When is Femasys' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our FEMY earnings forecast.
How were Femasys' earnings last quarter?: Femasys Inc. (NASDAQ:FEMY) announced its earnings results on Wednesday, November, 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. The business earned $0.27 million during the quarter. Femasys had a negative net margin of 886.22% and a negative trailing twelve-month return on equity of 48.96%.

When did Femasys IPO?: (FEMY) raised $35 million in an IPO on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.
What is Femasys' stock symbol?: Femasys trades on the NASDAQ under the ticker symbol "FEMY."
Who are Femasys' major shareholders?: Femasys' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.16%) and Tri Locum Partners LP (0.90%).
View institutional ownership trends.
How do I buy shares of Femasys?: Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Femasys' stock price today?: One share of FEMY stock can currently be purchased for approximately $1.08.
How much money does Femasys make?: Femasys (NASDAQ:FEMY) has a market capitalization of $12.76 million and generates $1.18 million in revenue each year. The company earns $-7,540,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.
How can I contact Femasys?: The official website for the company is www.femasys.com. The company can be reached via phone at 770-500-3910 or via email at ir@femasys.com.

This page (NASDAQ:FEMY) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial